Market News AIOpen the app

Celldex said its Phase 2 study of barzolvolimab for atopic dermatitis did not achieve its main goals.

ResultsRead the original at rss.globenewswire.com
Bad for CLDX

Celldex's study missed its main measures and the company's own bar for continuing this use, weakening barzolvolimab's outlook for atopic dermatitis. The drug remains in study for other conditions with earlier positive Phase 3 results, but those do not undo this failure.

CLDX · Celldex Therapeutics

AI read · Bad for CLDX

The AI's read

This weakens the case for developing barzolvolimab for atopic dermatitis because it missed the study's main measures and Celldex's own bar for continuing. The drug remains in study for 3 other conditions, and Celldex has reported positive Phase 3 results there. Those results support other uses, but they do not change the failed result in this one.

Get alerts for CLDX

Follow Celldex Therapeutics (CLDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLDX
Free on the App Store and Google Play, or on the web.